Abivax Announces Temporary Suspension of Share Trading on Euronext Paris

Paris, July 1, 2026 - Abivax SA, a clinical-stage biotech firm, has initiated a temporary halt in trading its ordinary shares on Euronext Paris. This decision aligns with the company's previously announced public offering of American Depositary Shares in the U.S. The halt began at the market opening and is intended to facilitate investor allocations and pricing announcements for the offering.

The trading suspension is expected to last until a further update from Abivax. The indication is that normal trading activities on Euronext Paris will resume around 3:30 p.m. CEST the same day. The move seeks to ensure a smooth transition as the company progresses with its public offering plans.

The company continues to focus on developing treatments that leverage natural immune mechanisms for chronic inflammatory diseases, with its lead product currently in Phase 3 trials.